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Abstract
Introduction: Timely diagnosis of invasive candidiasis (IC) remains difficult as the clinical presentation is not
specific and blood cultures lack sensitivity and need a long incubation time. Thus, non-culture-based methods for
diagnosing IC have been developed. Mannan antigen (Mn) and anti-mannan antibodies (A-Mn) are present in
patients with IC. On behalf of the Third European Conference on Infections in Leukemia, the performance of these
tests was analysed and reviewed.
Methods: The literature was searched for studies using the commercially available sandwich enzyme-linked
immunosorbent assays (Platelia™, Bio-Rad Laboratories, Marnes-la-Coquette, France) for detecting Mn and A-Mn in
serum. The target condition of this review was IC defined according to 2008 European Organization for Research
and Treatment of Cancer/Mycoses Study Group criteria. Sensitivity, specificity and diagnostic odds ratios (DOR)
were calculated for Mn, A-Mn and combined Mn/A-Mn testing.
Results: Overall, 14 studies that comprised 453 patients and 767 controls were reviewed. The patient populations
included in the studies were mainly haematological and cancer cases in seven studies and mainly intensive care
unit and surgery cases in the other seven studies. All studies but one were retrospective in design. Mn sensitivity
was 58% (95% confidence interval [CI], 53-62); specificity, 93% (95% CI, 91-94) and DOR, 18 (95% CI 12-28). A-Mn
sensitivity was 59% (95% CI, 54-65); specificity, 83% (95% CI, 79-97) and DOR, 12 (95% CI 7-21). Combined Mn/A-Mn
sensitivity was 83% (95% CI, 79-87); specificity, 86% (95% CI, 82-90) and DOR, 58 (95% CI 27-122). Significant
heterogeneity of the studies was detected. The sensitivity of both Mn and A-Mn varied for different Candida
species, and it was the highest for C. albicans, followed by C. glabrata and C. tropicalis. In 73% of 45 patients with
candidemia, at least one of the serological tests was positive before the culture results, with mean time advantage
being 6 days for Mn and 7 days for A-Mn. In 21 patients with hepatosplenic IC, 18 (86%) had Mn or A-Mn positive
test results at a median of 16 days before radiological detection of liver or spleen lesions.
Conclusions: Mn and A-Mn are useful for diagnosis of IC. The performance of combined Mn/A-Mn testing is
superior to either Mn or A-Mn testing.
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Invasive candidiasis (IC) is an important infectious com-
plication in immunocompromised patients and is asso-
ciated with severe morbidity and high mortality [1].
However, the timely diagnosis of IC remains difficult
as the clinical presentation is not specific and blood
cultures lack sensitivity (30-50%) and need a long incu-
bation time [2-5]. Moreover, in patients with haematolo-
gical malignancies, thrombocytopenia precludes invasive
diagnostic procedures during the acute phase of infec-
tion. Thus, obtaining a microbiological diagnosis in deep
tissue invasive infection, such as hepatosplenic candidia-
sis in patients with neutropenia, is based on ultrasound,
computed tomography (CT) or magnetic resonance ima-
ging (MRI) [6,7]. In these cases, only a presumptive
diagnosis is often obtained as these images are not
specific for Candida infection. As a consequence, micro-
biological markers would be extremely helpful in con-
firming or excluding the diagnosis of an invasive fungal
disease [8].
Noninvasive, non-culture-based methods for diagnos-
ing invasive fungal disease have been studied extensively
and are now being used in daily clinical practice. The
importance of serological methods has been reflected in
the criteria for diagnosing invasive fungal disease, which
include galactomannan and b-D-glucan as microbiologi-
cal criteria for diagnosing specific fungal infection [9].
The use of circulating Candida antigens, metabolites
and antibodies for the diagnosis of IC include the detec-
tion of mannan antigen (Mn), anti-mannan antibodies
(A-Mn), enolase and arabinitol and have been reported
in several studies [10-13].
In 2005, the European Conference on Infections in
Leukemia (ECIL) was created by several groups, includ-
ing the European Group for Blood and Marrow Trans-
plantation, the European Organization for Treatment
and Research of Cancer, the European Leukemia Net
and the Immunocompromised Host Society, with the
main purpose of elaborating guidelines, or recommenda-
tions, for the management of infections in leukaemia
and haematopoietic stem cell transplant patients. During
the third ECIL meeting held in September 2009, the
performance of noninvasive diagnostic tests for fungal
infections, such as galactomannan, b-D-glucan, Mn and
A-Mn and cryptococcal antigen, was analysed. This
paper is focused on the use of Mn antigen and A-Mn
antibodies in the diagnosis of invasive candidiasis.
Mn is a major component of the C. albicans cell wall,
composing up to 7% of the cell dry weight, and is one
of the main Candida antigens that circulate during
infection [14]. Different tests have been developed to
detect Mn antigen or A-Mn antibodies in serum, and
they differ significantly as far as sensitivity is concerned
[15]. The methods developed to detect Mn antigen in
serum include latex agglutination and immunoenzymatic
assays [15]. Initial observations showed that mannane-
mia was preferentially observed in the absence of A-Mn
antibodies and that, vice versa, high levels of A-Mn anti-
bodies were generally not associated with mannanemia
[16]. The observation of this balance between Mn epi-
tope circulation and A-Mn antibody response in
patients’ serum has led to the idea that the combined
detection of mannanemia and A-Mn antibodies by
enzyme-linked immunosorbent assays (ELISAs) may be
a useful diagnostic procedure [17,18]. Therefore, ELISAs
have been developed for the detection of Mn, a major
Candida cell wall constituent, and A-Mn and are mar-
keted as Platelia™ Candida Antigen (Bio-Rad Labora-
tories, Marnes-la-Coquette, France) and Platelia™
Candida Antibody [16,19]. Nowadays, ELISA is the
assay most frequently used in Europe and consequently
is the one with the most scientific data published.
Therefore, the aim of this study was to review the litera-
ture of the past 10 years (since the Platelia™ tests have
been developed and marketed) on the use of Mn and A-
Mn for diagnosing IC.
Materials and methods
The recommendations of ECIL are based on a review of
the English-language literature following a predefined
methodology [20]. The quality of evidence and level of
recommendation were graded according to the standard
scoring system of the Infectious Diseases Society of
America and the U.S. Public Health Service for rating
recommendations in clinical guidelines [21]. The
strength of recommendation was graded as follows: (A)
good evidence to support a recommendation for use, (B)
moderate evidence to support a recommendation for
use, and (C) poor evidence to support a recommenda-
tion. The quality of evidence was graded as follows: (I)
evidence from at least one properly randomised, con-
trolled trial; (II) evidence from at least one well-designed
clinical trial, without randomisation, from cohort or
case-controlled analytic studies (preferably from more
than one centre), from multiple time series or from dra-
matic results from uncontrolled experiments; and (III)
evidence based on the opinions of respected authorities,
clinical experience, descriptive studies or reports of
expert committees.
Studies and patients
All of the studies that assessed the diagnostic accuracy
of Mn and/or A-Mn antibody detection using immu-
noenzymatic methods in any patient population, with
either prospective or retrospective data collection, were
eligible. The tests under evaluation were the commer-
cially available sandwich ELISAs (Platelia™) for detecting
Mn and A-Mn antibodies in serum. Studies addressing
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that used tests other than ELISA were not included in
this review to minimise the problem of comparing
results obtained with different assays.
The target condition of this review is candidemia and
any other form of IC. The following reference standards
can be used to define the target condition: autopsy or
the criteria of the European Organization for Treatment
and Research of Cancer and Mycoses Study group
(EORTC/MSG) for defining invasive fungal infections
[7,9]. According to these criteria, proven candidiasis is
defined as histopathologic, cytopathologic or direct
microscopic examination of a specimen obtained by
needle aspiration or biopsy from a normally sterile site
(other than mucous membranes). The specimen must
have evidence of yeast cells or recovery of a yeast by
culture of a sample obtained using a sterile procedure
(including a freshly placed drain) from a normally sterile
site showing a clinical or radiological abnormality con-
sistent with an infectious process.
The definition of probable invasive, that is, hepatos-
plenic, candidiasis, has changed during the past 6 years.
In the first version of EORTC/MSG diagnostic criteria,
probable Candida infection was diagnosed in patients
with risk factors who had small, peripheral target-like
abscesses (that is, bull’s-eye lesions) in liver and/or
spleen demonstrated by CT, MRI or ultrasound, as well
as an elevated serum alkaline phosphatase level; sup-
porting microbiological criteria were not required for
probable category [7]. On the contrary, the EORTC/
MSG criteria published in 2008 defined disseminated
hepatosplenic candidiasis as the presence, in high-risk
patients, of characteristic lesions in the liver or spleen
after an episode of candidemia within the previous 2
weeks. However, this definition is problematic because
blood cultures are frequently negative in these patients,
despite repeated attempts to culture a large volume of
blood and each lumen of intravenous catheters.
Patients with proven or probable invasive candidiasis
defined according to EORTC/MSG criteria were consid-
ered as true positive subjects with IC. Subjects without
IC were considered as true negatives. Patients with pos-
sible IC, that is, the presence of highly suggestive symp-
toms without microbiological documentation, were not
included in the assessment of the performance of the
test because of the uncertainty whether they represent
true or false positives.
Search methods for identification of studies
The MEDLINE electronic database was searched with
the following terms: Candida, candidiasis, candidemia,
antigen, antibody, diagnosis, mannan antigen, anti-man-
nan antibodies, ELISA, and Platelia™ entered both as
text word and MeSH terms if present. The literature
search was performed by one of the authors (MM), and
the studies published between 1 January 1998 and 9 Jan-
uary 2010 were considered. To identify additional stu-
dies, we entered relevant studies selected from the
above sources into PubMed and then used the related
articles feature and checked the reference lists of all
relevant manuscripts. Additionally, review articles and
abstracts from the main conferences from the past 5
years (American Society of Hematology Annual Meet-
ing, Interscience Conference on Antimicrobial Agents
and Chemotherapy, Infectious Diseases Society of Amer-
ica Annual Meeting, European Congress of Clinical
Microbiology and Infectious Diseases and Congress on
Trends in Medical Mycology) were screened for any
other relevant studies. The following articles were
excluded from the review: animal or in vitro studies,
articles in languages other than English, case reports
and studies that included less than 10 patients (includ-
ing cases and controls).
Statistical analysis
Our reference standard was the set of EORTC/MSG cri-
teria. To calculate tests’ accuracy and to reflect the cate-
gories that are used in clinical practice, we considered
the patients with proven and probable IC as having
invasive Candida infection (true positives) and patients
without candidiasis as the control group (true negatives).
This resulted in two-by-two tables: positive or negative
Mn antigen, A-Mn antibody or both Mn and A-Mn in
each of two groups. The data in the two-by-two tables
were used to calculate sensitivity and specificity for each
study, while 95% confidence intervals (95% CI) were cal-
culated using the Freeman-Tukey test. For the number
of true positives, true negatives, false positives and false
negatives that were reported, all of the following were
calculated: the diagnostic odds ratios (DORs) with 95%
CI. In case of two-by-two tables containing zeroes, 0.5
was added to all counts in the table, which is a com-
monly used method to calculate an approximation of
DOR [22,23]. Median values of sensitivity, specificity
and DOR were calculated for all of the available studies.
Individual study results, together with overall pooled
results, were presented graphically by plotting the esti-
mates of sensitivity, specificity and DOR (and their
respective 95% CIs) in forest plots. The heterogeneity of
the studies was investigated using a c
2 test. P values of
0.5 or lower were considered statistically significant.
Results
Literature research and description of studies
Overall, 556 literature search results were retrieved and
screened for relevant information. There were 22 studies
that described the use of Mn and A-Mn in various
patient populations. Eight studies used tests other than
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Page 3 of 14Table 1 Description of the studies that used Platelia™ mannan (Mn) and anti-mannan (A-Mn) assay (in reverse
chronological order)
First author,
year of
publication,
country,
type of
study
Cutoff value
of Mn and
A-Mn,
number of
samples to
declare
positive
Underlying
condition/risk
factor for IC
Diagnostic criteria for
Candida infection
(number of patients
with different sites of
IC)
No. of patients
and no. of
samples
No. (%) of
patients
with C.
albicans
No. of
control
patients
and
samples
Type of control group
1 Verduyn
Lunel et al.,
2009,
Netherlands,
retrospective
[31]
Mn ≥ 0.25
ng/ml
A-Mn ≥ 5
AU/ml
Single
sample
Chemotherapy Culture from a sterile
site
21 and 242
divided into:
neutropenic for
less or more
than 15 days: 10
and 11,
respectively
12 (57%) 30 and
390
Patients with
haematological
malignancies
2 Ellis et al.,
2009, UAE,
prospective
[26]
Mn ≥ 0.25
ng/ml; A-Mn
≥ 2.5 AU/ml
Two
consecutive
samples
positive for
both Mn and
A-Mn
Haematological
malignancies
IC EORTC
(5 candidemia and 7
hepatosplenic IC)
12 and 216 1 74 High-risk patients
without IC (50 febrile
neutropenia, 24 mould
infection)
3 Sendid et al.,
2008, France,
retrospective
[37]
Mn ≥ 0.5 ng/
ml
A-Mn ≥ 10
AU/ml
Single
sample
Mostly ICU and
surgery, 14;
haematological
malignancy 2.
Candidemia 18 and 69 18 (100%) None -
4 Oliveri et al.,
2008, Italy,
ND [24]
Mn ≥ 0.5 ng/
ml
Two samples
Neonatal ICU Candidemia and
probable IC defined as
presence of sign and
symptoms despite broad
spectrum antibiotics +
Candida colonisation
18 (12
candidemia and
6 probable IC)
and 18
ND 52 and
52
Neonates from the same
ward without IC
5 Alam et al.,
2007, Kuwait,
retrospective
[28]
Mn ≥ 0.5 ng/
ml
A-Mn ≥ 10
AU/ml
Single
sample
Mostly ICU; 2
haematological
malignancies
Candidemia 27 and 32 18 (67%) 26 and
26
10 patients with vaginal
candidiasis, 16 healthy
controls (39 patients
with clinically suspected
IC were not considered
as a control group)
6 Fujita et al.,
2006, Japan,
retrospective
[29]
Mn ≥ 0.5 ng/
ml
Single
sample
Solid tumour,
69;
haematological
malignancy, 8;
other, 28
Candidemia 105 and 251 49 (33%) 175 and
178
Febrile patients with or
without bacteraemia
7 Prella et al.,
2005,
Switzerland,
retrospective
[25]
Mn ≥ 0.25
ng/ml
A-Mn ≥ 5
AU/ml
Two samples
Haematological
malignancies
IC proven and probable
according to EORTC
(12 candidemia, 14
hepatosplenic IC)
26 and ND 5 (19%) 25 and
163
Patients with
haematological
malignancy and
noncandidal infection
8 White et al.,
2005, UK,
retrospective
[32]
Mn ≥ 0.5 ng/
ml
Single
sample
Haematological
malignancies,
14; other, 6
IC EORTC for
haematological patients
and culture or
underlying condition +
signs and symptoms +
colonisation for
nonhaematological
(2 proven, 13 probable
hepatosplenic and 5
probable in non
haematological)
20 and ND ND 67 and
ND
High-risk patients (not
included 18
haematology patients
with possible IC)
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Page 4 of 14ELISA and were not included in this review. Thus, 14
studies on Mn/A-Mn immunoenzymatic tests were
reviewed. The description of these 14 studies is outlined
in Table 1 in chronological order.
The number of patients included in the studies varied
from 7 to 105, with a median of 25 patients per study.
Four studies were performed exclusively in patients with
haematological malignancies, three studies were con-
ducted in patients mostly with cancer or haematological
malignancy and the remaining seven studies included
mostly or exclusively patients from intensive care unit
(ICU) or surgery wards (among them was one study
from a neonatal ICU). Overall, among 453 case patients
described, 123 (27%) had haematological disorders. A
control group was included in only 11 of 14 studies and
most frequently consisted of patients with similar risk
factors, but without IC and sometimes with other docu-
mented infections. Four studies included healthy blood
donors as control samples.
All of the studies performed included Mn antigen test-
ing, while only 11 of them also searched for A-Mn anti-
bodies. Thus, the sensitivity of the test could be
evaluated in all studies (14 for Mn, 10 for A-Mn and
combined Mn/A-Mn), but the specificity could be evalu-
ated in only 11 studies that included a control group. In
all 11 studies, Mn specificity was evaluated, while the
specificity of A-Mn or combined Mn/A-Mn testing was
reported in only 7 and 6 papers, respectively.
For Platelia™ Mn antigen and A-Mn antibody testing, the
values of 0.5 ng/mL for Mn and 10 arbitrary units (AU)/
mL for A-Mn are defined as positive according to the
manufacturer, while the values 0.25-0.5 ng/mL for Mn
Table 1 Description of the studies that used Platelia™ mannan (Mn) and anti-mannan (A-Mn) assay (in reverse chrono-
logical order) (Continued)
9 Sendid et al.,
2004, France,
retrospective
[33]
Mn ≥ 0.5 ng/
ml
Single
sample
Mostly ICU and
surgery, 21;
haematological
malignancy, 3;
other, 2.
Signs and symptoms +
culture (19 candidemia,
other culture sites
included BAL in 5,
bronchial biopsy and
pleural liquid in 1)
26 and 90 18 (69%) 118 and
148
70 healthy donors, 10
patients with IFD, 24
high risk patients, mostly
ICU, 14 subjects with
high rheumatoid factor
titres
10 Sendid et al.,
2003, France,
retrospective
[27]
Mn ≥ 0.5 ng/
ml
A-Mn ≥ 10
AU/ml
Single
sample
Haematological
malignancies
Candidemia due to C.
tropicalis
7 and 82 0 12 and
48
Febrile neutropenic
patients without
candidemia
11 Sendid et al.,
2002,
retrospective
[17]
Mn ≥ 0.5 ng/
ml
A-Mn ≥ 10
AU/ml
Single
sample
Mostly ICU and
surgery, 41;
haematological
malignancies,
10; other, 12
Signs and symptoms +
culture (58 candidemia,
2 peritoneum cultures, 2
spleen cultures)
63 and 204 21 (33%)
and
C. glabrata,
12; C.
tropicalis,
10; C.
parapsilosis,
10; C. krusei,
8
None -
12 Persat et al.,
2002, France,
retrospective
[34]
Mn ≥ 0.5 ng/
ml
A-Mn ≥ 10
AU/ml
Single
sample
Cancer, 7;
haematological
malignancy, 6;
surgery, 2;
other, 7
IC EORTC 22 and 22 14 (64%) 38 and
38
10 healthy individuals, 10
patients at risk but
without IC, 18 with
Candida colonisation
13 Yera et al.,
2001, France,
retrospective
[18]
Mn ≥ 0.5 ng/
ml
A-Mn ≥ 10
AU/ml
Single
sample
ICU and
surgery, 32;
haematological
malignancies,
11; other, 2
Candidemia 45 and 137 23 (51%) None -
14 Sendid et al.,
1999, France,
retrospective
[16]
Mn ≥ 0.5 ng/
ml
A-Mn ≥ 10
AU/ml
Single
sample
ICU and
surgery, 32;
haematological
malignancy, 1,
other, 10
Signs and symptoms +
culture from a sterile site
(23 candidemia, 14
surgery drain cultures)
43 and 162 43 (100%) 150 and
230
98 healthy blood donors
and 52 hospitalised
patients without IC (of
them 29 with IFD: 12 IA,
13 cryptococcosis and 4
PCP)
UAE, United Arab Emirates; Ab, antibody; Ag, antigen; IC, invasive candidiasis; IA, invasive aspergillosis; IC, invasive candidiasis; ICU, intensive care unit; IFD,
invasive fungal disease; ND, no data; PCP, Pneumocystis jiroveci pneumonia.
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nate. Most studies defined a positive result according to
the cutoff value recommended by the manufacturer in a
single serum sample. In two studies, a result was regarded
as positive if in two samples Mn or A-Mn or Mn in one
and A-Mn in one were above intermediate cutoff thresh-
olds [24,25]. Additionally, one prospective study differed
significantly as far as sampling and threshold values are
concerned. In the study by Ellis et al. [26], the cutoff used
for A-Mn was two to four times lower than the others (2.6
vs. 5 or 10), but different criteria were used to define a
positive Mn/A-Mn result, that is, two consecutive samples
positive for both Mn and A-Mn. Therefore, for A-Mn and
Mn/A-Mn testing, the results obtained in this way are
reported. For each study, the cutoff values used are
reported in Table 1.
Sensitivity, specificity and diagnostic odds ratio
The per-patient values of sensitivity and specificity (with
95% CI) with respect to the reference diagnostic method
of Mn, A-Mn and combined Mn/A-Mn testing are
reported in Table 2. The overall pooled results, together
with the results of single studies and their respective
weight in meta-analysis, are reported as forest plots in
Figures 1, 2 and 3 for Mn, A-Mn and combined Mn/A-
Mn testing, respectively.
The median sensitivity of all the studies was 62%, ran-
ging from 31% in the study by Prella et al. [25] to 100%
in the study by Sendid et al. that reported seven cases of
candidemia due to C. tropicalis [27]. The overall pooled
per-patient sensitivity of Mn was evaluated in 14 studies
in 453 patients and resulted in 58% sensitivity (95% CI,
53-62). Antibody testing was performed in 10 studies
with a total of 284 patients, and the sensitivity of the anti-
body assay was 59% (95% CI, 54-65), with the median
value of 57%, ranging from 44% to 100% [17,26]. The
median sensitivity of combined Mn/A-Mn testing (that
is, when either Mn- or A-Mn-positive results were con-
sidered, except for the study by Ellis et al.[ 2 6 ] ,i nw h i c h
a different definition of positivity was used as reported
above) was 86%, ranging from 71% to 100%. The pooled
overall sensitivity of Mn/A-Mn was 83% (95% CI, 79-87).
Eleven studies included a control group, allowing the
assessment of specificity and the calculation of DOR.
The specificity of Mn testing was performed in all 11
studies and resulted in a range from 65% in the study
by Ellis et al.[ 2 6 ]t o1 0 0 %i nt h es t u d yr e p o r t e db y
Alam et al. [28], with an overall pooled specificity of
93% (95% CI, 91-94). For A-Mn testing, the specificity
was evaluated in seven studies and with a pooled overall
result of 83% (95% CI, 79-97), ranging from 38% to
100% (the lowest value was reported in the study by
Ellis et al. [26]). The overall specificity of combined
Mn/A-Mn assay was 86% (95% CI, 82-90).
The DORs were calculated for Mn, A-Mn and Mn/A-
Mn testing and differed significantly between the studies
(Figures 1, 2, 3). Overall, DOR was the highest in the
case of combined Mn/A-Mn testing (58; 95% CI, 27-122),
followed by Mn testing (18; 95% CI, 12-28) and A-Mn
(12; 95% CI, 7-21).
Significant heterogeneity of the studies was detected
for the sensitivity of Mn (P < 0.0001) and A-Mn (P =
0.0002); the specificity of Mn, A-Mn and Mn/A-Mn
(P < 0.0001 for all); and the DORs of Mn (P = 0.004)
and A-Mn (P = 0.01). To reduce the heterogeneity, the
same pooled values were calculated with the exclusion
of the one study that differed significantly from the
others, that is, the study by Ellis et al. [26]. However,
even with this study excluded, the heterogeneity
remained significant (data not shown). When the stu-
dies were grouped by underlying disease (haematological
or cancer and ICU or surgery), the heterogeneity disap-
peared in some of the subgroups, but this effect might
be due to the low number of studies included in each
subgroup (data not shown). Therefore, the final overall
pooled results are reported for all the studies available
(Figures 1, 2, 3).
Additionally, per-sample values were reported in five
studies in which there were more samples than patients.
The per-sample values were not considered significantly
different from per-patient data for the study by Alam
et al. [28], where only five patients had two samples
instead of one. The overall per-sample sensitivity was
lower than the per-patient sensitivity, but the specificity
remained high (Table 3).
Different Candida species
The sensitivity of both Mn and A-Mn varied for differ-
ent Candida species, and it was the highest for C. albi-
cans, followed by C. glabrata and C. tropicalis [27,29].
In particular, according to the results reported by Sen-
did et al. [17], the sensitivity for the detection of Mn
was 58%-70% for infections caused by C. albicans, C.
glabrata and C. tropicalis, while it was 25%-30%
for infections caused by C. parapsilosis and C. krusei
(Table 4). The difference was even more pronounced in
the study by Fujita et al.[ 2 9 ] ,w h e r et h es e n s i t i v i t yf o r
C. albicans was 78% compared to 15% and 0 for
C. parapsilosis and C. krusei, respectively. Even though
the sensitivity varied among the studies, it was clearly
lower in cases of C. parapsilosis and C. krusei, probably
because of the lower amount of Mn produced and
released by these species [19,30].
Timing of diagnosis
Another point worth analysing while reviewing studies on
non-culture-based diagnostic methods is the time to diag-
nosis of IC compared to traditional methods. This
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both haematological and ICU patients [17,18,24,25,31]. In
73% of 45 patients with candidemia, at least one of the ser-
ological tests was positive before the culture results [18],
and in patients in whom the Mn and/or A-Mn antibody
tests were positive before blood culture, the mean time
advantage was 6 days for Mn and 7 days for A-Mn. These
findings were confirmed in another study of 63 patients, in
whom at least one of the serological tests was positive
before yeast growth occurred in 60% of patients for whom
a serum sample was available before blood culture
sampling and an increase in serological test positivity to
85% was observed for sera obtained on the date of positive
culture, irrespective of the Candida species isolated [17].
Similarly, in a recent study of patients undergoing che-
motherapy, serological tests were positive significantly ear-
lier than culture, that is, in a median of 23 days for A-Mn
and 1 day earlier for Mn [31]. Even in the neonatal ICU,
Mn could be detected before the day of blood sampling in
8 of 12 patients with proven IC, with the time advantage
of 8.5 days [24]. Last but not least, in 21 patients with
hepatosplenic lesions highly suggestive of candidiasis, 18
Table 2 Per-patient sensitivity, specificity and diagnostic odds ratio (DOR), with 95% confidence intervals of mannan
antigen (Mn), anti-mannan antibodies (A-Mn) and combined Mn/A-Mn testing for separate studies, median of the
studies and totala
Study Sensitivity (95% CI), absolute numbers:
true positives/total
Specificity (95% CI), absolute numbers:
true negatives/total
DOR (95% CI)
Mn A-Mn Mn/A-Mn Mn A-Mn Mn/A-Mn Mn A-Mn Mn/A-
Mn
1. Verduyn Lunel
et al., 2009 [31]
0.38 (0.18-
0.62), 8/21
0.52 (0.30-
0.74), 11/21
0.71 (0.48-
0.89), 15/21
0.83 (0.65-
0.94), 25/30
0.90 (0.73-
0.98), 27/30
- 3.1 (0.8-
11.3)
9.9 (2.3-
43)
-
2. Ellis et al., 2009
[26]
b
0.75 (0.43-
0.95), 9/12
1.00 (0.74-
1.00), 12/12
1.00 (0.74-
100), 12/12
0.65 (0.53-
0.76), 48/74
0.38 (0.27-
0.50), 28/74
0.80 (0.69-
0.88), 59/74
5.5 (1.4-
22.3)
15.3 (0.9-
268.9)
96 (5.4-
1712)
3. Sendid et al.,
2008 [37]
0.67 (0.41-
0.87), 12/18
0.78 (0.52-
0.94), 14/18
0.94 (0.73-
0.99), 17/18
--- - - -
4. Oliveri et al.,
2008 [24]
0.94 (0.73-
0.99), 17/18
- - 0.94 (0.84-
0.99), 49/52
- - 277.7
(27-
2852.3)
--
5. Alam et al., 2007
[28]
0.48 (0.29-
0.68), 13/27
0.52 (0.32-
0.71), 14/27
0.81 (0.62-
0.94), 22/27
1.00 (0.87-
1.00), 26/26
0.92 (0.75-
0.99), 24/26
0. 92 (0.75-
0.99), 24/26
49.3 (2.7-
891.8)
12.9 (2.5-
65.8)
52.8 (9.3-
300.5)
6. Fujita et al.,
2006 [29]
0.53 (0.43-
0.63), 56/105
- - 0.92 (0.87-
0.96), 161/175
13.1 (6.7-
25.6)
--
7. Prella et al.,
2005 [25]
0.31 (0.14-
0.52), 8/26
0.81 (0.61-
0.93), 21/26
0.88 (0.70-
0.98), 23/26
0.96 (0.80-
0.99), 24/25
0.88 (0.69-
0.97), 22/25
0.84 (0.64-
0.95), 21/25
(all 4
colonised)
10.7 (1.2-
93.1)
30.8 (6.5-
145.3)
40.3 (8.1-
201.3)
8. White et al.,
2005 [32]
0.75 (0.51-
0.91), 15/20
- - 0.97 (0.90-
0.99), 65/67
- - 97.5
(17.2-
551.8)
--
9. Sendid et al.,
2004 [33]
0.69 (0.48-
0.86), 18/26
- - 0.97 (0.93-
0.99), 115/118
- - 86.3
(20.9-
355.7)
--
10. Sendid et al.,
2003 [27]
1.00 (0.59-
1.00), 7/7
0.71 (0.29-
0.96), 5/7
1.00 (0.59-
1.00), 7/7
0.92 (0.62-
0.99), 11/12
1.00 (0.74-
1.00), 12/12
0.92 (0.62-
0.99), 11/12
115 (4.1-
3213.5)
55 (2.2-
1346,2)
115 (4.1-
3213.5)
11. Sendid et al.,
2002 [17]
0.52 (0.39-
0.65), 33/63
0.44 (0.32-
0.58), 28/63
0.76 (0.64-
0.86), 48/63
--- - - -
12. Persat et al.,
2002 [34]
0.86 (0.65-
0.97), 19/22
0.59 (0.36-
0.79), 13/22
0.95 (0.77-
0.99), 21/22
0.79 (0.63-
0.90), 30/38
0.63 (0.46-
0.78), 24/38
0.53 (0.36-
0.69), 20/38
23.8 (5.6-
100.8)
2.48 (0.9-
7.3)
23.3 (2.8-
191.5)
13. Yera et al.,
2001 [18]
0.58 (0.42-
0.72), 26/45
0.53 (0.38-
0.68), 24/45
0.78 (0.63-
0.89), 35/45
--- - - -
14. Sendid et al.,
1999 [16]
0.42 (0.27-
0.58), 18/43
0.56 (0.40-
0.71), 24/43
0.84 (0.69-
0.93), 36/43
0.98 (0.94-
0.99), 147/150
0.97 (0.92-
0.99), 145/150
0.95 (0.90-
0.98), 142/150
35.3 (9.7-
128.6)
36.6
(12.5-
107.4)
91.3
(31.1-
268.4)
Median of all the
studies (range)
0.62 (0.31-1.0) 0.57 (0.44-1.0) 0.86 (0.71-1.0) 0.94 (0.65-1.0) 0.9 (0.38-1.0) 0. 88 (0.53-
0.92)
Pooled overall 0.58 (0.53-
0.62), 259/453
0.59 (0.54-
0.65), 166/284
2
0.83 (0.79-
0.87), 236/
284
c
0.93 (0.91-
0.94), 701/
767
d
0.83 (0.79-
0.87), 282/
355
e
0.86 (0.82-
0.90), 277/
325
f
18.6
(12.5-
27.7)
d
12.1 (7-
20.8)
e
57.5
(27.1-
122)
f
aNR, not reported; -, no data.
bAbsolute numbers calculated on basis of reported percentage sensitivity and specificity values.
cAvailable for 10 studies.
dData
from 11 studies.
eData from 7 studies.
fData from 6 studies.
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Page 7 of 14(86%) had positive Mn and/or A-Mn antibody tests at a
median of 16 days before radiological detection of liver or
spleen lesions [25]. In fact, the study by Prella et al.[ 2 5 ]
was the first one to show the usefulness of Mn and A-Mn
serum level determination in patients with suspected
hepatosplenic IC, allowing the diagnosis of this complica-
tion before neutrophil recovery in the majority of patients.
The clinical utility of serological testing in this setting was
confirmed by the study of Ellis et al., in which 7 of 12
patients with IC had the hepatosplenic form [26].
Figure 1 Single-study and overall sensitivity, specificity and diagnostic odds ratio (DOR) for mannan antigen testing. Total number of
patients and a weight of each single study in meta-analysis are reported.
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Page 8 of 14Possible invasive candidiasis and colonisation
Obviously, the most interesting patients are those with
p o s s i b l eI C ,w h e r ec u l t u r eis probably not sensitive
enough to detect candidemia and where a more sensitive
method, such as antigen testing, might prove extremely
helpful. The fact that Mn is more sensitive than culture
is indirectly proved by the fact that Mn sensitivity in
groups of patients with possible candidemia is higher
Figure 2 Single-study and overall sensitivity, specificity and DOR for anti-mannan antibody testing. Total number of patients and a
weight of each single study in meta-analysis are reported.
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Page 9 of 14than that in controls but lower than that in culture-posi-
tive IC. For example, in the study by White et al. [32], 5
of 18 patients with possible Candida infection had posi-
t i v er e s u l t so nM nt e s t i n g .S i m i l a r l y ,i n3 9p a t i e n t sw i t h
clinically suspected IC, Mn and A-Mn were present in
16% and 29% of patients, respectively [28].
The colonisation with Candida, particularly if multiple
sites are colonised, has always been feared to be a
potential reason for the lower specificity of Mn or A-
Mn testing. Indeed, lower specificities are generally
observed in colonised subjects, and Candida colonisa-
tion has been reported to result in detectable A-Mn
Figure 3 Single-study and overall sensitivity, specificity and DOR for combined mannan antigen and anti-mannan antibody testing.
Total number of patients and a weight of each single study in meta-analysis are reported.
Mikulska et al. Critical Care 2010, 14:R222
http://ccforum.com/content/14/6/R222
Page 10 of 14antibody levels in approximately 30% of uninfected
patients [16]. Therefore, we reviewed the data on test
performance in patients with Candida colonisation.
Overall, four studies included patients with Candida
colonisation in their control population. In the study by
Verduyn Lunel et al. [31], 19 of 21 patients and 20 of 30
controls were colonised with Candida (mostly C. albi-
cans) as detected by two consecutive samples from
mouthwashes and/or faeces. However, in the logistic
regression analysis, neither prior colonization nor super-
ficial Candida infections were associated with the
detection of Mn or A-Mn. On the contrary, A-Mn was
detected in patients with Candida colonisation in the
s t u d yb yS e n d i det al. [16], in which one of the control
groups comprised 23 ICU patients, of whom 19 had Can-
dida colonisation. In this group, only one patient (4%)
had positive Mn, but 6 (26%) of 19 had positive A-Mn
results [16]. Similarly, in a control group of 10 patients
with vaginal candidiasis, 2 patients (20%) had a positive
Mn result [28], while among 15 ICU patients colonised
with Candida at two sites or more, only 1 patient (7%)
had a positive A-Mn result [33]. Higher rates of false
positives were reported in the study by Persat et al.[ 3 4 ] ,
w h e r e1 8o f3 8c o n t r o lp a t i e n t sh a dCandida colonisa-
tion, 4 (22%) had positive results for Mn and 8 (44%) had
positive results for A-Mn. Finally, in the study by Ellis
et al. [26], where 60% of 74 control patients had Candida
colonisation, the specificities of both Mn and A-Mn were
significantly lower than reported in other studies. In par-
ticular, the specificity was only 21% if two consecutive
positive results for either Mn or A-Mn were evaluated
[26]. Such a low specificity differs from the results of the
other studies and may be related to the fact that a parti-
cularly low cutoff value was used for A-Mn testing.
Table 3 Per sample sensitivity, specificity, with 95% confidence intervals of Mn, A-Mn and combined Mn/A-Mn testing
Study Mn A-Mn Mn/A-Mn Mn A-Mn Mn/A-Mn
Verduyn Lunel, 2009 [31] 0.17 (0.13-0.22),
41/240
0.39 (0.33-0.45),
93/238
- 0.95 (0.92-0.97),
379/390
0.87 (0.83-0.90),
347/384
-
Sendid, 2008 [37] 0.67 (0.55-0.77),
46/69
0.35 (0.25-0.47),
24/69
--- -
Fujita, 2006 [29] 0.45 (0.39-0.51),
112/251
- - 0.92 (0.87-0.95),
164/178
Sendid et al., 2003 [27] 0.54 (0.43-0.64),
44/82
0.23 (0.15-0.33),
19/82
0.68 (0.58-0.77),
56/82
0.98 (0.89-0.99),
47/48
1 (0.93-1.0),
48/48
0.98 (0.89-
0.99),
47/48
Sendid et al., 2002 [17] 0.35 (0.29-0.42),
72/204
0.27 (0.22-0.34),
56/204
0.55 (0.49-0.62),
113/204
-- -
Sendid et al., 1999 [16] 0.27 (0.20-0.34),
43/162
0.39 (0.32-0.47),
63/162
0.62 (0.55-0.69),
101/162
0.99 (0.96-0.99),
227/230
0.96 (0.93-0.98),
221/230
0.94 (0.91-
0.97),
218/230
Median of all the studies
(range)
0.40 (0.17-0.67) 0.35 (0.23-0.39) 0.62 (0.55-0.68) 0.97 (0.92-0.99) 0.96 (0.87-1.0) 0.96 (0.94-
0.98)
-, no data.
Table 4 Sensitivity of Mn and/or A-Mn testing in different Candida species
Species Study Number of isolates Sensitivity
Mn A-Mn Mn/A-Mn
C. albicans Fujita et al., 2006 [29] 49 78%
Sendid et al., 2002 [17] 21 62% 67% 100%
C. tropicalis Sendid et al., 2002 [17] 10 70% 60% 80%
Fujita et al., 2006 [29] 9 67%
Sendid et al., 2003 [27] 7 100% 71% 100%
C. glabrata Sendid et al., 2002 [17] 12 58% 83% 83%
Fujita et al., 2006 [29] 11 36%
C. guilliermondi Fujita et al., 2006 [29] 11 27%
C. parapsilosis Fujita et al., 2006 [29] 20 15%
Sendid et al., 2002 [17] 10 30% 10% 40%
C. krusei Sendid et al., 2002 [17] 8 25% 38% 50%
Fujita et al., 2006 [29] 2 0
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Page 11 of 14Even though ELISA is licensed to be used in serum
only, Verduyn Lunel et al. [35] reported an interesting
use of Mn testing in cerebrospinal fluid (CSF) in five
patients with Candida meningitis. In fact, four of them
tested positive for Mn in CSF. Additionally, a recent
study performed in preterm infants found that Mn
detection in bronchoalveolar lavage fluid might be useful
for early identification and preemptive treatment of can-
didemia in these patients [36].
Discussion
The review of the use of Mn and A-Mn in patients with
confirmed or suspected IC showed that these noninva-
sive tests might be useful for microbiological confirma-
tion or exclusion of the diagnosis of IC. The overall
performance of combined Mn/A-Mn testing was super-
ior to either Mn or A-Mn testing alone.
In most of the studies, the diagnostic performance of
Mn and A-Mn tests was compared to blood culture as a
gold standard, and they were positive before the results
of the latter, thus allowing for earlier diagnosis of IC.
Despite the fact that prompt diagnosis and treatment
are crucial for prognosis in IC, these tests are not
intended to replace blood cultures, and special consid-
eration for their use concerns the 40%-50% of patients
with IC in whom blood cultures remain constantly
negative. There is no reason why the specificity for IC,
established by comparison with blood culture, could not
apply to the patients with negative blood cultures. Thus,
for patients with significant mannanemia or A-Mn anti-
bodies, antifungal treatment might be considered.
Even though high overall specificity and sensitivity
were found in the aforementioned studies, the optimal
way to use these tests in daily clinical practice remains
to be defined. In fact, only one study was prospective,
and the results obtained differed importantly from other
studies [26]. Whereas numerous factors might have
been responsible for the low specificity reported by Ellis
et al. [26], only further prospective studies will define
the strategies of Mn/A-Mn testing for diagnosis of can-
didemia in times when b-D-glucan use is becoming
more and more popular. In particular, Mn/A-Mn testing
might be seen as complementary in cases with a positive
b-D-glucan result, given that b-D-glucan is nonspecific.
In such cases, positive Mn or A-Mn results might indi-
cate fungal disease due to Candida, while a negative
Mn/A-Mn test could indicate infection caused by other
fungi. The utility of such an approach should be
investigated.
Another aspect of Mn/A-Mn testing is its utility in
diagnosing hepatosplenic candidiasis in neutropenic
patients who do not yet show evidence of radiological
lesions because of the absence of neutrophils. Mn/A-Mn
testing might provide a valid clue to the aetiology of
fever in such infections. Considering that the sensitivity
is highest for C. albicans and C. tropicalis species, this
approach seems the most promising in patients who do
not receive fluconazole prophylaxis and thus are at risk
for infections caused by species other than C. krusei or
C. glabrata.
Several limitations of this review have to be acknowl-
edged. First, despite the fact that we included studies
conducted more than 10 years ago, the number of stu-
dies is limited, and publication bias, that is, reporting
only the results of good performance of a diagnostic
test, might be present. Second, only one of the studies is
prospective in design [26]; thus more studies are war-
ranted to evaluate the clinical everyday utility of a single
positive result. Third, the studies analysed were quite
heterogeneous as far as patient population was con-
cerned. Indeed, some studies included patients from the
ICU and surgery, while others concentrated on those
with haematological malignancies. It is true that these
are two entirely different groups that require different
management strategies, including, for example, the
administration of antifungal prophylaxis and the possibi-
lity of postponing therapy. Moreover, control groups
were not included in some studies, while in others they
differed from healthy individuals to patients at high risk
for candidemia but with negative blood cultures. How-
ever, in 7 of 11 studies, the control population included
patients with exactly the same underlying condition as
the study cases, and none of the studies considered only
healthy individuals as controls. Fourth, different cutoff
values were used, even though the thresholds of 2.5 mg/
ml Mn and 5 AU/ml for A-Mn were used most fre-
quently. Last but not least, the sampling and criteria
used for defining a positive case varied between the stu-
dies, with some regarding a result as positive only if two
tests were above the cutoff value. On the other hand,
the advantages of these assays include no need for inva-
sive procedures; good sensitivity and specificity; standar-
dised, simple and commercially available kits; and
affordable costs. Therefore, even though the design of
the studies was not uniform, the reported results are
encouraging, and considering the increasing interest and
importance of noninvasive, non-culture-based proce-
dures in diagnosing fungal disease, Mn/A-Mn testing
might offer substantial help to clinicians caring for high-
risk patients.
Prospective studies are warranted to confirm the
advantages of Mn and A-Mn testing in everyday clinical
practice. Different populations who are at high risk of
developing IC, such as patients with haematological
malignancies, patients admitted to the ICU or those
who have undergone abdominal surgery, should be stu-
died separately to draw reliable conclusions about the
positive and negative predictive value of a single or
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Page 12 of 14multiple positive results. Moreover, randomised, pro-
spective studies might confirm benefits in terms of out-
come if preemptive antifungal treatment is started early
on the basis of positive Mn or A-Mn results.
Conclusions
On the basis of the literature review, Mn antigen and A-
Mn antibody offer diagnostic help in patients with sus-
pected IC. Therefore, the following recommendations
have been made by the Third European Conference on
Infections in Leukemia (ECIL-3) members: the use of
combined Mn/A-Mn is preferred over Mn or A-Mn
alone for diagnosing invasive Candida infection, BII;
combined Mn/A-Mn testing is useful for supporting the
diagnosis of candidemia, CII; and combined Mn/A-Mn
testing is useful for diagnosing hepatosplenic candidiasis,
BIII.
Key messages
￿ Diagnosis of IC is difficult in high-risk patients,
thus noninvasive tests that detect Candida compo-
nents in the serum of patients with IC have been
developed.
￿ Performance of Mn and A-Mn antibody tests was
analysed and reviewed on behalf of ECIL-3.
￿ Overall, 14 studies that included haematological
malignancy and ICU patients were reviewed.
￿ Moderate sensitivity and good specificity of Mn
and A-Mn were found (Mn, 58% and 93%; A-Mn,
59% and 83%, respectively).
￿ Combined Mn/A-Mn testing was better than each
test alone (sensitivity 83% and specificity 86%).
￿ Combined Ma/A-Mn testing improves the diagno-
sis of IC in ICU or surgery and haematology
patients.
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